Stoke Therapeutics (STOK) EPS (Weighted Average and Diluted) (2021 - 2026)
Stoke Therapeutics' quarterly EPS (Weighted Average and Diluted) came in at -$0.79 in Q1 2026, down 141.58% year-on-year from $1.9 in Q1 2025, and up 18.56% quarter-over-quarter from -$0.97 in Q4 2025.
Stoke Therapeutics has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at -$0.79 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 141.58% year-over-year to -$0.79; the trailing twelve-month figure through Mar 2026 stood at -$2.81 (down 451.25% YoY), and the FY2025 full-year result was -$0.12, up 92.73% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.79, up from -$0.97 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $1.9 in Q1 2025, with the low at -$0.97 in Q4 2025.
- Average EPS (Weighted Average and Diluted) over 5 years is -$0.44, with a median of -$0.6 recorded in 2023.
- Peak annual rise in EPS (Weighted Average and Diluted) reached 433.33% in 2025, while the deepest fall reached 470.59% in 2025.
- Tracing STOK's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.65 in 2022, then increased by 7.69% to -$0.6 in 2023, then soared by 71.67% to -$0.17 in 2024, then tumbled by 470.59% to -$0.97 in 2025, then climbed by 18.56% to -$0.79 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.79 (Q1 2026), -$0.97 (Q4 2025), and -$0.65 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - | -0.79 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.79 |
| Dec 31, 2025 | -0.97 |
| Sep 30, 2025 | -0.65 |
| Jun 30, 2025 | -0.40 |
| Mar 31, 2025 | 1.90 |
| Dec 31, 2024 | -0.17 |
| Sep 30, 2024 | -0.47 |
| Jun 30, 2024 | -0.46 |
| Mar 31, 2024 | -0.57 |
| Dec 31, 2023 | -0.60 |
| Sep 30, 2023 | -0.55 |
| Jun 30, 2023 | -0.69 |
| Mar 31, 2023 | -0.53 |
| Dec 31, 2022 | -0.65 |
| Sep 30, 2022 | -0.66 |
| Jun 30, 2022 | -0.63 |
| Mar 31, 2022 | -0.66 |
| Dec 31, 2021 | -1.28 |
| Sep 30, 2021 | -0.60 |
| Jun 30, 2021 | -0.60 |